Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 7680 results

  1. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    In development [GID-TA11108] Expected publication date: TBC

  2. Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

    In development [GID-TA11126] Expected publication date: TBC

  3. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

  4. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued [GID-TA11175]

  5. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued [GID-TA10494]

  6. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

  7. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

  8. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued [GID-TA10375]

  9. PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

    Discontinued [GID-TA10402]

  10. Pelareorep for untreated pancreatic cancer [ID1074]

    Discontinued [GID-TA10689]

  11. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued [GID-TA10686]

  12. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued [GID-TA10687]

  13. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued [GID-TA10447]

  14. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued [GID-TA10144]